JP2014114296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014114296A5 JP2014114296A5 JP2014006383A JP2014006383A JP2014114296A5 JP 2014114296 A5 JP2014114296 A5 JP 2014114296A5 JP 2014006383 A JP2014006383 A JP 2014006383A JP 2014006383 A JP2014006383 A JP 2014006383A JP 2014114296 A5 JP2014114296 A5 JP 2014114296A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- calcium
- modulator composition
- calcium modulator
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 28
- 229910052791 calcium Inorganic materials 0.000 claims 28
- 239000011575 calcium Substances 0.000 claims 28
- 239000000203 mixture Substances 0.000 claims 18
- 210000002966 serum Anatomy 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 102000003982 Parathyroid hormone Human genes 0.000 claims 8
- 108090000445 Parathyroid hormone Proteins 0.000 claims 8
- 239000000199 parathyroid hormone Substances 0.000 claims 8
- 229960001319 parathyroid hormone Drugs 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 208000020084 Bone disease Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 206010008723 Chondrodystrophy Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims 1
- 208000037848 Metastatic bone disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000002804 Osteochondritis Diseases 0.000 claims 1
- 201000009859 Osteochondrosis Diseases 0.000 claims 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010052306 Periprosthetic osteolysis Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000008919 achondroplasia Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000008416 bone turnover Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000002849 chondrocalcinosis Diseases 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000000010 osteolytic effect Effects 0.000 claims 1
- 208000005368 osteomalacia Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000028198 tertiary hyperparathyroidism Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85959706P | 2006-11-16 | 2006-11-16 | |
| US60/859,597 | 2006-11-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537400A Division JP5645408B2 (ja) | 2006-11-16 | 2007-11-16 | 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014114296A JP2014114296A (ja) | 2014-06-26 |
| JP2014114296A5 true JP2014114296A5 (https=) | 2015-02-26 |
Family
ID=39468623
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537400A Active JP5645408B2 (ja) | 2006-11-16 | 2007-11-16 | 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド |
| JP2014006383A Pending JP2014114296A (ja) | 2006-11-16 | 2014-01-17 | 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537400A Active JP5645408B2 (ja) | 2006-11-16 | 2007-11-16 | 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8987200B2 (https=) |
| EP (1) | EP2086321B1 (https=) |
| JP (2) | JP5645408B2 (https=) |
| KR (1) | KR101552843B1 (https=) |
| CN (2) | CN103961686A (https=) |
| AU (1) | AU2007325387B2 (https=) |
| CA (1) | CA2669914C (https=) |
| WO (1) | WO2008067199A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2559228C (en) | 2004-04-21 | 2016-06-21 | Enobia Pharma Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| JP5645408B2 (ja) | 2006-11-16 | 2014-12-24 | カイ ファーマシューティカルズ インコーポレーティッド | 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド |
| CA2989778C (en) * | 2007-01-19 | 2020-06-30 | Kai Pharmaceuticals, Inc. | Method of modifying peptide compositions |
| US8999932B2 (en) * | 2009-07-29 | 2015-04-07 | Kai Pharmaceuticals, Inc. | Therapeutic agents for reducing parathyroid hormone levels |
| KR101761388B1 (ko) * | 2010-07-30 | 2017-07-25 | 큐어백 아게 | 트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체 |
| WO2012050673A1 (en) * | 2010-10-14 | 2012-04-19 | Wisconsin Alumni Research Foundation | Methods for the treatment of x-linked hypophosphatemia and related disorders |
| HRP20161566T1 (hr) * | 2011-06-08 | 2017-02-24 | Kai Pharmaceuticals, Inc. | Terapijski agensi za reguliranje serumskog fosfora |
| CN109985228A (zh) | 2011-11-10 | 2019-07-09 | 凯伊药品公司 | 拟钙剂及其使用方法 |
| US9579273B2 (en) * | 2011-12-14 | 2017-02-28 | The Kitasato Institute | Delivery of therapeutic agents by a collagen binding protein |
| MA38724B1 (fr) * | 2013-06-28 | 2017-11-30 | Amgen Inc | Formulation liquide stable d'amg 416 (velcalcétide) |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| MX389350B (es) | 2014-12-05 | 2025-03-19 | Alexion Pharma Inc | Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones. |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| CN108350440A (zh) | 2015-08-17 | 2018-07-31 | 阿雷克森制药公司 | 碱性磷酸酯的制造 |
| JP6868617B2 (ja) | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定 |
| JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| JP7613826B2 (ja) | 2016-04-01 | 2025-01-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| WO2018148573A1 (en) | 2017-02-10 | 2018-08-16 | The Board Of Trustees Of The University Of Arkansas | Collagen-binding agent compositions and methods of using the same |
| EP3600383A4 (en) | 2017-03-31 | 2020-10-28 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS |
| CN107899019B (zh) * | 2017-11-23 | 2020-04-21 | 湘潭大学 | 一种键合细胞穿透肽的智能型高分子键合药及其制备方法 |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| CN112349362B (zh) * | 2019-08-08 | 2025-06-20 | 深圳先进技术研究院 | 一种甲状旁腺激素分泌监测与调控系统 |
| CA3161266A1 (en) | 2019-12-09 | 2021-06-17 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| AU2021337652B2 (en) | 2020-09-04 | 2025-01-30 | Alexion Pharmaceuticals, Inc. | Methods for treating bone mineralization disorders |
| BR112023016048A2 (pt) | 2021-02-12 | 2023-11-14 | Alexion Pharma Inc | Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos |
| US12403179B2 (en) | 2021-02-18 | 2025-09-02 | The Board Of Trustees Of The University Of Arkansas | Release of growth factors at wound healing stages |
| EP4353248A4 (en) * | 2021-06-08 | 2024-10-23 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | CALCIUM-SENSITIVE RECEPTOR AGONIST COMPOSITION AND APPLICATION THEREOF |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602116A (en) * | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| US5869473A (en) * | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| CA1333616C (en) * | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| US5246925A (en) * | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| AU9131091A (en) | 1990-11-07 | 1992-06-11 | Scripps Research Institute, The | Peptides that inhibit platelet binding of adhesion molecules |
| US6031003A (en) * | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| WO1995006056A1 (en) * | 1993-08-20 | 1995-03-02 | University Of Medicine & Dentistry Of New Jersey | Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same |
| US5783405A (en) | 1994-02-01 | 1998-07-21 | Terrapin Technologies, Inc. | Rapid screening method for effectors of signal transduction |
| CA2145214A1 (en) | 1995-02-28 | 1996-08-29 | Rick E. Preddie | Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US5688489A (en) * | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
| US5895368A (en) * | 1996-09-23 | 1999-04-20 | Medisystems Technology Corporation | Blood set priming method and apparatus |
| WO1998017299A1 (en) | 1996-10-18 | 1998-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific activators of protein kinase c, methods and compositions |
| US6258774B1 (en) | 1998-03-19 | 2001-07-10 | University Of Medicine And Dentistry Of New Jersey | Carrier for in vivo delivery of a therapeutic agent |
| JP2000336099A (ja) * | 1999-05-27 | 2000-12-05 | Sekisui Chem Co Ltd | ペプチド及びｃ型肝炎抗体検出用試薬 |
| US6274169B1 (en) * | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
| US6051567A (en) * | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
| AU7895601A (en) * | 2000-07-18 | 2002-01-30 | Bone Care Int Inc | Stabilized 1alpha-hydroxy vitamin d |
| US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
| US20020168354A1 (en) | 2000-11-10 | 2002-11-14 | Daria Mochly-Rosen | psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia |
| WO2002057413A2 (en) * | 2001-01-18 | 2002-07-25 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for activation and inhibition of delta pkc |
| US20030091640A1 (en) | 2001-02-08 | 2003-05-15 | Srinivasan Ramanathan | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents |
| US20030036627A1 (en) * | 2001-02-16 | 2003-02-20 | Montelaro Ronald C. | Virus derived antimicrobial peptides |
| AU2002247724B2 (en) | 2001-02-23 | 2008-02-07 | Polyphor Ltd. | Template-fixed peptidomimetics with antimicrobial activity |
| JP2005287302A (ja) | 2002-04-03 | 2005-10-20 | Haruhiko Fujiwara | ポリペプチドの架橋方法 |
| US20040018976A1 (en) * | 2002-05-14 | 2004-01-29 | Feder John N. | Polynucleotide encoding novel human G-protein coupled receptors, and splice variants thereof |
| WO2004093821A2 (en) | 2003-04-22 | 2004-11-04 | Hawaii Biotech, Inc. | Treatment of anthrax infection using inhibitors of lethal factor protease activity |
| EP1680446B1 (en) | 2003-11-05 | 2007-10-31 | Pevion Biotech Ltd. | Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens |
| CA2549052A1 (en) * | 2003-12-11 | 2005-06-30 | The Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific antagonists of protein kinase c |
| US7939634B2 (en) | 2004-01-27 | 2011-05-10 | Compugen Ltd. | Polynucleotides encoding polypeptides and methods using same |
| US7265092B2 (en) * | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
| WO2007027510A2 (en) * | 2005-08-30 | 2007-03-08 | Acologix, Inc. | Regulation of mineral and skeletal metabolism |
| CA2644089A1 (en) * | 2005-09-19 | 2007-03-29 | Kai Pharmaceuticals, Inc. | Protein kinase c peptide modulators of angiogenesis |
| WO2007038172A2 (en) | 2005-09-23 | 2007-04-05 | Nitto Denko Corporation | Guanidinium carriers |
| JP5645408B2 (ja) | 2006-11-16 | 2014-12-24 | カイ ファーマシューティカルズ インコーポレーティッド | 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド |
| CA2989778C (en) | 2007-01-19 | 2020-06-30 | Kai Pharmaceuticals, Inc. | Method of modifying peptide compositions |
| WO2009046220A2 (en) | 2007-10-02 | 2009-04-09 | Mdrna, Inc. | Lipopeptides for delivery of nucleic acids |
| EP2229473A4 (en) | 2007-12-07 | 2011-02-02 | Steven A Goldstein | IDENTIFICATION OF TOXIN LIGANDS |
| US8999932B2 (en) * | 2009-07-29 | 2015-04-07 | Kai Pharmaceuticals, Inc. | Therapeutic agents for reducing parathyroid hormone levels |
-
2007
- 2007-11-16 JP JP2009537400A patent/JP5645408B2/ja active Active
- 2007-11-16 EP EP07871514.1A patent/EP2086321B1/en active Active
- 2007-11-16 CN CN201410164043.3A patent/CN103961686A/zh active Pending
- 2007-11-16 CN CN200780050006.8A patent/CN101668421B/zh active Active
- 2007-11-16 CA CA2669914A patent/CA2669914C/en active Active
- 2007-11-16 US US11/941,857 patent/US8987200B2/en active Active
- 2007-11-16 AU AU2007325387A patent/AU2007325387B2/en active Active
- 2007-11-16 KR KR1020097012356A patent/KR101552843B1/ko active Active
- 2007-11-16 WO PCT/US2007/085024 patent/WO2008067199A2/en not_active Ceased
-
2014
- 2014-01-17 JP JP2014006383A patent/JP2014114296A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014114296A5 (https=) | ||
| ZA202508806B (en) | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant | |
| WO2009103105A3 (en) | Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders | |
| EP4406599A3 (en) | Use of c-type natriuretic peptide variants to treat skeletal dysplasia | |
| MX2012008999A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| JP2015536991A5 (https=) | ||
| WO2015110957A3 (en) | Hybridosomes, compositions comprising the same, processes for their production and uses thereof | |
| WO2008118017A3 (en) | Prame derived peptides and immunogenic compositions comprising these | |
| WO2011014707A3 (en) | Therapeutic agents for reducing parathyroid hormone levels | |
| HRP20160798T1 (hr) | Rekombinantni antigeni iz rsv | |
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
| JOP20210230A1 (ar) | صياغات صيدلانية | |
| WO2015114395A9 (en) | Process for the preparation of vortioxetine salts | |
| JP2011517675A5 (https=) | ||
| MX370890B (es) | Composición que comprende sulfato de salbutamol. | |
| WO2019197563A3 (en) | Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation | |
| WO2010128521A3 (en) | Short-chain peptides as parathyroid hormone (pth) receptor agonist | |
| WO2011011072A3 (en) | Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59 | |
| JP2011510066A5 (https=) | ||
| WO2015024022A3 (en) | Designed peptides for tight junction barrier modulation | |
| JP2013542196A5 (https=) | ||
| JP2017533952A5 (https=) | ||
| MX2011004176A (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo. |